-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice
Clinical Trail Perspective: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Future perspectives on the pharmacological management of depression
Sarah Yates, Eleanor Smith, Hamid A Alhaj, R Hamish McAllister-Williams
Review: Clinical Trail Outcomes: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation
-
Optimism and oncology trials: help or hindrance?
Blair Henry, Michael Szego
Editorial: Clinical Investigation